328 related articles for article (PubMed ID: 10469432)
1. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
2. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
Hattori S; Maekawa M; Nakamura S
Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
[TBL] [Abstract][Full Text] [Related]
3. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
[TBL] [Abstract][Full Text] [Related]
4. [Molecular genetics of neurofibromatosis type 1].
Suzuki H; Takahashi K; Shibahara S
Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
6. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of rasGAP and neurofibromatosis gene product activities.
Bollag G; McCormick F
Nature; 1991 Jun; 351(6327):576-9. PubMed ID: 1904555
[TBL] [Abstract][Full Text] [Related]
8. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
Stang S; Bottorff D; Stone JC
Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
[TBL] [Abstract][Full Text] [Related]
9. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
Parada LF; Kwon CH; Zhu Y
Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
[TBL] [Abstract][Full Text] [Related]
10. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis.
Gutmann DH; Boguski M; Marchuk D; Wigler M; Collins FS; Ballester R
Oncogene; 1993 Mar; 8(3):761-9. PubMed ID: 8437860
[TBL] [Abstract][Full Text] [Related]
12. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
[TBL] [Abstract][Full Text] [Related]
13. Coupling of ras p21 signalling and GTP hydrolysis by GTPase activating proteins.
McCormick F
Philos Trans R Soc Lond B Biol Sci; 1992 Apr; 336(1276):43-7; discussion 47-8. PubMed ID: 1351295
[TBL] [Abstract][Full Text] [Related]
14. [NF1 (neurofibromatosis type 1)].
Maruta H; Nur-e-Kamal
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1422-6. PubMed ID: 9309135
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
Marshall MS; Hettich LA
Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
[TBL] [Abstract][Full Text] [Related]
16. Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.
Hingtgen CM; Roy SL; Clapp DW
Neuroscience; 2006; 137(2):637-45. PubMed ID: 16298082
[TBL] [Abstract][Full Text] [Related]
17. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
Dasgupta B; Li W; Perry A; Gutmann DH
Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
19. Differences in the interaction of p21c-Ha-ras-GMP-PNP with full-length neurofibromin and GTPase-activating protein.
DiBattiste D; Golubic M; Stacey D; Wolfman A
Oncogene; 1993 Mar; 8(3):637-43. PubMed ID: 8437847
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis type 1 gene mutations in neuroblastoma.
The I; Murthy AE; Hannigan GE; Jacoby LB; Menon AG; Gusella JF; Bernards A
Nat Genet; 1993 Jan; 3(1):62-6. PubMed ID: 8490657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
